RE:RE:RE:RE:RE:RE:RE:expiration of optionsI suppose that we will know soon enough. But thus far the scientific evidence points towards pelareorep being effective, and biomarkers have been identified as surrogate endpoints, predictive diagnostics have been developed for timely and synergistic addition of pelareorep to ICIs , and the business case for pelareorep as a platform drug to be used in multiple cancers has been clear.